Filing Flows › Fulgent Genetics (FLGT) › Guidance history
Fulgent Genetics (FLGT) guidance history: what it guided and what it reported
Fulgent Genetics gave guidance in 4 earnings releases on file since May 1, 2026.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $350M (May 1, 2026) → lowered $330M–$340M (Jul 30, 2026) → reaffirmed $330M–$340M (Nov 5, 2026) | — | to be reported | — |
Operating cash flow
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $112M (Nov 5, 2026) | — | to be reported | — |
The latest quarter
Fulgent Genetics, Q3 2026: revenue $90.4M (+8% year over year), operating margin -24.9%, net loss $13.3M, operating cash flow $109M. The chart follows the revenue to costs, profit and cash.
Questions
Does Fulgent Genetics beat its guidance?
Fulgent Genetics gave guidance in 4 earnings releases on file since May 1, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.